SCHEDULE 13G: Lynx1 Capital Management Discloses 9.99% Stake in Precision BioSciences Inc.
Beneficial Ownership Report
Lynx1 Capital Management LP and Weston Nichols have reported a beneficial ownership of 9.99% in Precision BioSciences Inc., holding 766,051 shares of common stock as of December 31, 2024.
Summary
- Lynx1 Capital Management LP and Weston Nichols collectively reported beneficial ownership of 766,051 shares of Common Stock in Precision BioSciences Inc.
- This ownership represents 9.99% of the company's outstanding Common Stock.
- The percentage is calculated based on 7,671,059 shares of Common Stock outstanding as of October 31, 2024, as reported in the company's Form 10-Q.
- Both Lynx1 Capital Management LP and Weston Nichols share voting and dispositive power over all 766,051 shares.
- The filing is a Schedule 13G, indicating a passive investment purpose, with the reporting persons certifying that the securities were not acquired for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: The sentiment is slightly positive as it indicates an institutional investor has taken a significant stake, which can be interpreted as a vote of confidence. However, it's a passive filing and doesn't contain operational or financial news.
Positives
- The disclosure of a significant 9.99% stake by an institutional investor like Lynx1 Capital Management LP can be viewed as a vote of confidence in Precision BioSciences Inc.'s long-term prospects.
- The passive nature of the Schedule 13G filing suggests a strategic, non-activist investment, which may provide stability.
Risks
- The filing itself does not detail specific company risks, but the certification states the shares were not acquired for the purpose of changing or influencing control, meaning the investor is not seeking an active role in governance or strategic direction.
Future Outlook
This document, a Schedule 13G, is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.
Industry Context
This filing reflects an institutional investment in a biotechnology company, a common occurrence in the sector where specialized funds often take significant positions in firms with promising pipelines or technologies. Such investments can signal market confidence in the company's potential within the competitive biotech landscape.
Stakeholder Impact
- Shareholders: May view the significant institutional investment as a positive signal, potentially increasing investor confidence and interest in the stock.
- Company Management: Awareness of a large, passive institutional holder may influence strategic decisions, though the 13G explicitly states no intent to influence control.
Key Dates
| Date | Description |
|---|---|
| 2024-09-30 | End of quarterly period for which Precision BioSciences Inc.'s Form 10-Q was filed. |
| 2024-10-31 | Date as of which 7,671,059 shares of Common Stock were reported outstanding by Precision BioSciences Inc. |
| 2024-12-31 | Date of event which requires the filing of this Schedule 13G statement. |
| 2025-02-14 | Date the Schedule 13G statement was signed and filed. |
Keywords
Precision BioSciences Inc., Lynx1 Capital Management, Weston Nichols, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Biotechnology, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.